Sequence-specific targeting of IGF-I and IGF-IR genes by camptothecins
- PMID: 20179147
- PMCID: PMC2887256
- DOI: 10.1096/fj.09-132324
Sequence-specific targeting of IGF-I and IGF-IR genes by camptothecins
Abstract
We and others have clearly demonstrated that a topoisomerase I (Top1) inhibitor, such as camptothecin (CPT), coupled to a triplex-forming oligonucleotide (TFO) through a suitable linker can be used to cause site-specific cleavage of the targeted DNA sequence in in vitro models. Here we evaluated whether these molecular tools induce sequence-specific DNA damage in a genome context. We targeted the insulin-like growth factor (IGF)-I axis and in particular promoter 1 of IGF-I and intron 2 of type 1 insulin-like growth factor receptor (IGF-IR) in cancer cells. The IGF axis molecules represent important targets for anticancer strategies, because of their central role in oncogenic maintenance and metastasis processes. We chemically attached 2 CPT derivatives to 2 TFOs. Both conjugates efficiently blocked gene expression in cells, reducing the quantity of mRNA transcribed by 70-80%, as measured by quantitative RT-PCR. We confirmed that the inhibitory mechanism of these TFO conjugates was mediated by Top1-induced cleavage through the use of RNA interference experiments and a camptothecin-resistant cell line. In addition, induction of phospho-H2AX foci supports the DNA-damaging activity of TFO-CPT conjugates at specific sites. The evaluated conjugates induce a specific DNA damage at the target gene mediated by Top1.
Figures





Similar articles
-
In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.Nucleic Acids Res. 1997 Oct 15;25(20):4111-6. doi: 10.1093/nar/25.20.4111. Nucleic Acids Res. 1997. PMID: 9321666 Free PMC article.
-
Exploring the cellular activity of camptothecin-triple-helix-forming oligonucleotide conjugates.Mol Cell Biol. 2006 Jan;26(1):324-33. doi: 10.1128/MCB.26.1.324-333.2006. Mol Cell Biol. 2006. PMID: 16354702 Free PMC article.
-
Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.Biochemistry. 1995 May 30;34(21):7200-6. doi: 10.1021/bi00021a035. Biochemistry. 1995. PMID: 7766631
-
Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints.Curr Med Chem Anticancer Agents. 2004 Sep;4(5):429-34. doi: 10.2174/1568011043352777. Curr Med Chem Anticancer Agents. 2004. PMID: 15379698 Review.
-
Topoisomerase I inhibitors: camptothecins and beyond.Nat Rev Cancer. 2006 Oct;6(10):789-802. doi: 10.1038/nrc1977. Nat Rev Cancer. 2006. PMID: 16990856 Review.
Cited by
-
Targeted gene correction using psoralen, chlorambucil and camptothecin conjugates of triplex forming peptide nucleic acid (PNA).Artif DNA PNA XNA. 2011 Jan;2(1):23-32. doi: 10.4161/adna.2.1.15553. Artif DNA PNA XNA. 2011. PMID: 21686249 Free PMC article.
-
Sequence selectivity of the cleavage sites induced by topoisomerase I inhibitors: a molecular dynamics study.Nucleic Acids Res. 2013 Dec;41(22):10010-9. doi: 10.1093/nar/gkt791. Epub 2013 Sep 9. Nucleic Acids Res. 2013. PMID: 24021629 Free PMC article.
-
Regulation of transcription through light-activation and light-deactivation of triplex-forming oligonucleotides in mammalian cells.ACS Chem Biol. 2012 Jul 20;7(7):1247-56. doi: 10.1021/cb300161r. Epub 2012 May 11. ACS Chem Biol. 2012. PMID: 22540192 Free PMC article.
-
The past and presence of gene targeting: from chemicals and DNA via proteins to RNA.Philos Trans R Soc Lond B Biol Sci. 2018 Jun 5;373(1748):20170077. doi: 10.1098/rstb.2017.0077. Philos Trans R Soc Lond B Biol Sci. 2018. PMID: 29685979 Free PMC article. Review.
-
Oligonucleotide-Recognizing Topoisomerase Inhibitors (OTIs): Precision Gene Editors for Neurodegenerative Diseases?Int J Mol Sci. 2022 Sep 29;23(19):11541. doi: 10.3390/ijms231911541. Int J Mol Sci. 2022. PMID: 36232843 Free PMC article. Review.
References
-
- Baserga The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets. 2005;9:753–768. - PubMed
-
- Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther. 2007;6:1–12. - PubMed
-
- Samani A A, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007;28:20–47. - PubMed
-
- Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8:915–928. - PubMed
-
- Davies M, Gupta S, Goldspink G, Winslet M. The insulin-like growth factor system and colorectal cancer: clinical and experimental evidence. Int J Colorectal Dis. 2006;21:201–208. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials